Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Active Idiopathic Inflammatory Myopathy (Phase 2/3)
2024-512785-33-00Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM), juvenile dermatomyositis (JDM) and 3 more comparing Efgartigimod PH20 SC with Placebo SC (2 arms). Primary endpoint: Mean total improvement score (TIS) at week 52. Started Aug 2024; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)juvenile dermatomyositis (JDM)polymyositis (PM)antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on 2024-512785-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512785-33-00.